Manulife SG unveils two industry-first collaboration for cancer care, gut health

It will offer liquid biopsy for cancer care and gut health screening.

Manulife Singapore partnered with precision oncology company Guardant Health to provide eligible customers with access to the Guardant360 liquid biopsy test. It also partnered with AMILI, Southeast Asia's first gut microbiome insights company, to offer eligible customers access to advanced gut microbiome screening.

The initiative aims to support personalised cancer treatments for customers with advanced solid tumour cancers, potentially improving clinical outcomes.

The Guardant360 test offers comprehensive genomic profiling for all advanced solid cancers, identifying guideline-recommended biomarkers through a simple blood draw. 

Results are available within seven days after the sample is received, addressing gaps for patients who lack sufficient tumour tissue for standard biopsies. 

Its partnership with AMILI marks the first time such technology is available through a life insurer in Singapore.

The screening analyses the trillions of bacteria in an individual's gut, providing personalised insights to improve immunity, brain health, and nutrition.

These insights aim to help prevent lifestyle diseases and support overall well-being. Details on eligibility and redemption will be announced later.

AMILI’s test leverages the region's largest multi-ethnic Asian gut microbiome database to deliver precise insights tailored to the Asian population. 

Customers will receive a complimentary session with AMILI physicians to interpret their results and adopt a holistic approach to improving their health.